Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...

CardioSmart's vaccination toolkit offers valuable materials for both clinicians and patients, highlighting the significance of timely vaccination, the cardiovascular risks associated with not ...

VASCEPA (icosapent ethyl) is indicated to reduce cardiovascular risk in patients with elevated triglyceride levels and established cardiovascular disease. Disclaimer: This is an AI-generated ...

Corporation announced that additional in vitro mechanistic data with eicosapentaenoic acid, EPA, will be presented at the ...

“At Amarin, we continue to invest in the science behind VASCEPA/VAZKEPA to further explore the potential mechanistic activities of EPA, administered clinically in the form of our icosapent ethyl ...

NEWARK, Del, March 14, 2025 (GLOBE NEWSWIRE) -- The global Omega-3 market is poised for remarkable expansion, projected to surge from USD 5,785.1 million in 2025 to USD 13,323.1 million by 2035 ...

The science of VASCEPA, which is underpinned by the REDUCE-IT study and more than 500 additional publications, advancing understanding of the icosapent ethyl clinical benefits and mechanism of ...

Total Revenue: $228.6 million for 2024. Cash Position: $294 million with no debt at year-end 2024. Fourth Quarter Revenue: $62.3 million, including $60.1 million in net product revenue and $2.2 ...

Introduction: Icosapent ethyl (IPE) is indicated for the treatment of severe hypertriglyceridemia (triglycerides ≥500 mg/dl) and for reducing the risk of cardiovascular (CV) events in statin-treated ...

DUBLIN and BRIDGEWATER, N.J., March 12, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), today announced financial results for the fourth quarter of 2024 and provided a review of ...